UPCC 02215 Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases and Control Subjects

Study on Blood Markers in Pancreatic Diseases

Enrolling By Invitation
18 years or above
All
Phase N/A
100 participants needed
1 Location

Brief description of study

The purpose of this study is to collect blood samples to detect potential markers of pancreatic cancer in the blood and link these findings to medical and health information. Information from this study may help to provide insight into the detection of pancreas cancer in the blood before it can be found by other methods or provide a method of monitoring the status of pancreatic cancer throughout a treatment course. Another purpose of this study is to collect blood to create a biobank.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Pancreatic Diseases
  • Age: 18 years or above
  • Gender: All

Inclusion Criteria:

  1. The subject must be a patient at the Hospital of the University of Pennsylvania
    • The subject must be under evaluation and/or treatment for a pancreatic disease
    • The subject must be under evaluation and/or treatment for a non-pancreatic disease. For example, patients undergoing routine colonoscopy within the clinical practice will be asked to consent to provide control samples.
  2. The subject must be able to provide informed consent or have an acceptable surrogate

    capable of giving consent on the subject's behalf

  3. The subject must be 18 years of age or older

Exclusion Criteria:

  1. The subject or acceptable surrogate does not provide informed consent
  2. Subject is a prisoner
  3. Subject is under 18 years of age

The purpose of this study is to investigate potential markers of pancreatic cancer found in the blood. By collecting blood samples from participants, researchers aim to link these markers to medical and health information. This study may provide insights into detecting pancreatic cancer in the blood before other methods can, or offer a way to monitor the cancer's status during treatment. Additionally, the study involves collecting blood to create a biobank, which is a collection of biological samples for future research.

Participants in the study will have their blood samples collected. These samples will be analyzed to identify markers that may be associated with pancreatic cancer. The study does not involve any treatment changes but focuses on observing and collecting data from participants.

  • Who can participate: Participants must be 18 years or older, receiving evaluation or treatment for a pancreatic or non-pancreatic disease at the Hospital of the University of Pennsylvania, and able to provide informed consent or have a surrogate who can consent.
  • Study details: Participants will have their blood samples collected for analysis. The study aims to gather data without altering treatment plans.
Updated on 02 Jul 2026. Study ID: 15-0029
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator